Hansoh Reports P-III (ARTEMIS-008) Trial Data on Risvutatug Rezetecan for Advanced or Relapsed SCLC

Shots: Hansoh has reported the P-III (ARTEMIS-008) trial results assessing risvutatug rezetecan (Ris-Rez/HS-20093) vs topotecan in pts with advanced or relapsed SCLC after prior Pt-based therapy Trial met its 1EP of improved OS in the interim analysis, with consistent benefit also observed across 2EPs, incl. PFS; data will be presented at an upcoming conference Based on these findings, Hansoh Pharma plans to initiate communications with China’s NMPA CDE to advance preparations for a BLA Ref: Hansoh |  Image: Hansoh  | Press Release Related News: Hansoh Pharmaceutical Reports the EC Approval of Aumseqa for Non-small Cell Lung Cancer (NSCLC)  PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Hansoh Reports P-III (ARTEMIS-008) Trial Data on Risvutatug Rezetecan for Advanced or Relapsed SCLC appeared first on PharmaShots.